Published in Circulation on August 31, 2010
G protein-coupled receptor signalling in the cardiac nuclear membrane: evidence and possible roles in physiological and pathophysiological function. J Physiol (2011) 1.27
Alternative splicing regulates vesicular trafficking genes in cardiomyocytes during postnatal heart development. Nat Commun (2014) 1.08
VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Mol Med (2014) 1.08
Importance of myocyte-nonmyocyte interactions in cardiac development and disease. Circ Res (2012) 1.07
Pathologic function and therapeutic potential of exosomes in cardiovascular disease. Biochim Biophys Acta (2014) 1.06
Cross talk between cardiac myocytes and fibroblasts: from multiscale investigative approaches to mechanisms and functional consequences. Am J Physiol Heart Circ Physiol (2012) 1.02
NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth. J Clin Invest (2013) 0.99
Phenotypic screen quantifying differential regulation of cardiac myocyte hypertrophy identifies CITED4 regulation of myocyte elongation. J Mol Cell Cardiol (2014) 0.96
Endothelial cells overexpressing interleukin-8 receptors reduce inflammatory and neointimal responses to arterial injury. Circulation (2012) 0.95
Vinculin directly binds zonula occludens-1 and is essential for stabilizing connexin-43-containing gap junctions in cardiac myocytes. J Cell Sci (2014) 0.88
ROS regulate cardiac function via a distinct paracrine mechanism. Cell Rep (2014) 0.87
Ly6C(low) and not Ly6C(high) macrophages accumulate first in the heart in a model of murine pressure-overload. PLoS One (2014) 0.87
A potential role for integrin signaling in mechanoelectrical feedback. Prog Biophys Mol Biol (2012) 0.84
miR-182 Modulates Myocardial Hypertrophic Response Induced by Angiogenesis in Heart. Sci Rep (2016) 0.83
Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury. Br J Pharmacol (2015) 0.81
Overexpression of Cardiomyocyte α1A-Adrenergic Receptors Attenuates Postinfarct Remodeling by Inducing Angiogenesis Through Heterocellular Signaling. Arterioscler Thromb Vasc Biol (2015) 0.80
New insights in (inter)cellular mechanisms by heart failure with preserved ejection fraction. Curr Heart Fail Rep (2014) 0.80
Methylglyoxal-Induced Endothelial Cell Loss and Inflammation Contribute to the Development of Diabetic Cardiomyopathy. Diabetes (2016) 0.78
Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability. Biol Open (2016) 0.78
Cardiac-Secreted Factors as Peripheral Metabolic Regulators and Potential Disease Biomarkers. J Am Heart Assoc (2016) 0.77
Platelet endothelial cell adhesion molecule-1 mediates endothelial-cardiomyocyte communication and regulates cardiac function. J Am Heart Assoc (2015) 0.77
MicroRNA Clusters in the Adult Mouse Heart: Age-Associated Changes. Biomed Res Int (2015) 0.77
Endothelial dysfunction as a nexus for endothelial cell-cardiomyocyte miscommunication. Front Physiol (2014) 0.76
Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes. Cell Mol Life Sci (2017) 0.75
Three-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells. Development (2017) 0.75
Tissue Engineering Strategies for Myocardial Regeneration: Acellular Versus Cellular Scaffolds? Tissue Eng Part B Rev (2016) 0.75
High glucose facilitated endothelial heparanase transfer to the cardiomyocyte modifies its cell death signature. Cardiovasc Res (2016) 0.75
Insights into the Mechanisms Involved in Protective Effects of VEGF-B in Dopaminergic Neurons. Parkinsons Dis (2017) 0.75
Regulation of the microenvironment for cardiac tissue engineering. Regen Med (2017) 0.75
Combining Theoretical and Experimental Techniques to Study Murine Heart Transplant Rejection. Front Immunol (2016) 0.75
Cardiac spheroids as promising in vitro models to study the human heart microenvironment. Sci Rep (2017) 0.75
Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol (2002) 14.80
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2009) 12.34
MicroRNA-133 controls cardiac hypertrophy. Nat Med (2007) 11.68
Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol (2006) 10.71
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med (2007) 9.51
Plasma adiponectin levels and risk of myocardial infarction in men. JAMA (2004) 7.46
Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell (2009) 6.77
Multiple essential functions of neuregulin in development. Nature (1995) 5.66
Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest (2005) 5.53
Cardiac malformation in neonatal mice lacking connexin43. Science (1995) 5.51
Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature (1995) 5.51
Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest (2005) 5.48
HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell (2001) 4.75
Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature (2009) 4.68
p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature (2007) 4.63
The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res (2006) 4.38
Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Dev Cell (2009) 4.21
Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol (2001) 4.17
Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med (2004) 4.05
miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res (2008) 3.96
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med (2002) 3.74
Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem (2002) 3.22
TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res (2004) 3.20
Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem (2004) 3.01
Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension (2006) 3.01
Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat Med (2002) 2.89
Regulation of coronary blood flow during exercise. Physiol Rev (2008) 2.84
Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation (2005) 2.81
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A (2001) 2.77
The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer (2008) 2.67
Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res (2002) 2.59
The N-end rule pathway as a nitric oxide sensor controlling the levels of multiple regulators. Nature (2005) 2.55
Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc Res (2008) 2.43
Cardiac myocyte-specific excision of the beta1 integrin gene results in myocardial fibrosis and cardiac failure. Circ Res (2002) 2.36
Angiogenesis in skeletal and cardiac muscle. Physiol Rev (1992) 2.34
Phenotyping hypertrophy: eschew obfuscation. Circ Res (2003) 2.32
CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol (2000) 2.25
Fibroblast growth factor 2 control of vascular tone. Nat Med (1998) 2.21
Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res (2008) 2.15
Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J Clin Invest (2007) 2.12
Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem (2008) 2.03
Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol (2006) 2.02
Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation (2008) 1.99
Differences in gap junction channels between cardiac myocytes, fibroblasts, and heterologous pairs. Am J Physiol (1992) 1.95
The fuzzy logic of physiological cardiac hypertrophy. Hypertension (2007) 1.94
Bidirectional electrical communication between smooth muscle and endothelial cells in the pig coronary artery. Am J Physiol (1994) 1.93
Adiponectin actions in the cardiovascular system. Cardiovasc Res (2006) 1.92
Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest (2008) 1.89
Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes (2005) 1.87
Akt signaling mediates postnatal heart growth in response to insulin and nutritional status. J Biol Chem (2002) 1.86
Cardioprotection by adiponectin. Trends Cardiovasc Med (2006) 1.86
Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiology (Bethesda) (2007) 1.78
VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol (1996) 1.75
Cardiomyocyte-restricted deletion of connexin43 during mouse development. J Mol Cell Cardiol (2006) 1.70
Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept (2005) 1.68
Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation (2003) 1.66
Cardiac-myocyte-specific excision of the vinculin gene disrupts cellular junctions, causing sudden death or dilated cardiomyopathy. Mol Cell Biol (2007) 1.63
Structural and molecular mechanisms of gap junction remodeling in epicardial border zone myocytes following myocardial infarction. Circ Res (2009) 1.63
Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res (2000) 1.59
Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept (2004) 1.58
A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med (2008) 1.56
High incidence of cardiac malformations in connexin40-deficient mice. Circ Res (2003) 1.54
In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am J Physiol Heart Circ Physiol (2007) 1.54
Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice. J Clin Invest (2007) 1.49
Athlete's heart. Heart (2003) 1.45
Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation (2007) 1.45
Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther (2006) 1.44
Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc Natl Acad Sci U S A (2007) 1.43
Molecular and mechanical synergy: cross-talk between integrins and growth factor receptors. Cardiovasc Res (2004) 1.39
Gap junction-mediated cell-cell communication modulates mouse neural crest migration. J Cell Biol (1998) 1.37
NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. Am J Physiol (1999) 1.37
Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem (2006) 1.36
Endogenous regulation of cardiovascular function by apelin-APJ. Am J Physiol Heart Circ Physiol (2009) 1.34
Beta1 integrins participate in the hypertrophic response of rat ventricular myocytes. Circ Res (1998) 1.33
Cardiac alternans induced by fibroblast-myocyte coupling: mechanistic insights from computational models. Am J Physiol Heart Circ Physiol (2009) 1.33
The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity. J Clin Invest (2008) 1.26
An essential role for connexin43 gap junctions in mouse coronary artery development. Development (2002) 1.24
Connexins in vascular physiology and pathology. Antioxid Redox Signal (2009) 1.22
Altered pattern of vascular connexin expression in atherosclerotic plaques. Arterioscler Thromb Vasc Biol (2002) 1.21
Role of gap junctions in cardiac conduction and development: insights from the connexin knockout mice. Circ Res (2000) 1.20
Searching for miR-acles in cardiac fibrosis. Circ Res (2009) 1.19
Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun (2003) 1.19
Cardiac growth and angiogenesis coordinated by intertissue interactions. J Clin Invest (2007) 1.18
Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem (2008) 1.16
DIP2A functions as a FSTL1 receptor. J Biol Chem (2010) 1.16
Cardiomyocyte-specific endothelin A receptor knockout mice have normal cardiac function and an unaltered hypertrophic response to angiotensin II and isoproterenol. Mol Cell Biol (2003) 1.15
Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail (2006) 1.12
Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems. Br J Pharmacol (2007) 1.12
Regulation of vascular connexin43 gene expression by mechanical loads. Circ Res (1998) 1.09
Cdc42 is an antihypertrophic molecular switch in the mouse heart. J Clin Invest (2009) 1.08
Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways. Circ Res (2008) 1.07
Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. Am J Physiol (1996) 1.05
Integrins and proximal signaling mechanisms in cardiovascular disease. Front Biosci (Landmark Ed) (2009) 1.05
Control of type II transforming growth factor-beta receptor expression by integrin ligation. J Biol Chem (1999) 1.04
Distinct cardiac malformations caused by absence of connexin 43 in the neural crest and in the non-crest neural tube. Development (2006) 0.97
Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. Proc Natl Acad Sci U S A (2004) 0.97
Integrin binding angiopoietin-1 monomers reduce cardiac hypertrophy. FASEB J (2008) 0.96
Is angiotensin II a proliferative factor of cardiac fibroblasts? Cardiovasc Res (2002) 0.96
Transient expression of FRNK reveals stage-specific requirement for focal adhesion kinase activity in cardiac growth. Circ Res (2009) 0.94
Opposing cardiovascular roles for the angiotensin and apelin signaling pathways. J Mol Cell Cardiol (2006) 0.93
Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation (2004) 4.79
AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest (2004) 4.54
The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation (2003) 3.45
Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell (2004) 3.28
Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation (2008) 2.82
Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med (2002) 2.81
Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature (2011) 2.47
Syndecans: new kids on the signaling block. Circ Res (2005) 2.43
Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization. Cell (2011) 2.42
VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev Cell (2010) 2.37
ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway. Dev Cell (2012) 2.14
Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation (2005) 2.13
The FGF system has a key role in regulating vascular integrity. J Clin Invest (2008) 2.09
Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest (2004) 2.06
Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. J Exp Med (2007) 2.04
Medical device development: from prototype to regulatory approval. Circulation (2004) 1.90
Selective regulation of arterial branching morphogenesis by synectin. Dev Cell (2006) 1.77
Branching morphogenesis. Circ Res (2008) 1.77
Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation (2004) 1.71
Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. Mol Biol Cell (2005) 1.65
FGF regulates TGF-β signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Rep (2012) 1.63
Fibroblast growth factor regulation of neovascularization. Curr Opin Hematol (2008) 1.56
FGF-dependent regulation of VEGF receptor 2 expression in mice. J Clin Invest (2011) 1.56
The neuropilin 1 cytoplasmic domain is required for VEGF-A-dependent arteriogenesis. Dev Cell (2013) 1.54
Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB J (2004) 1.53
Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat Med (2003) 1.52
Endothelial-specific expression of mitochondrial thioredoxin improves endothelial cell function and reduces atherosclerotic lesions. Am J Pathol (2007) 1.52
Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice. J Clin Invest (2007) 1.49
Post-market approval surveillance: a call for a more integrated and comprehensive approach. Circulation (2004) 1.49
ERK1/2-Akt1 crosstalk regulates arteriogenesis in mice and zebrafish. J Clin Invest (2010) 1.45
VEGF signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol (2012) 1.44
Vascular endothelial growth factor and semaphorin induce neuropilin-1 endocytosis via separate pathways. Circ Res (2008) 1.43
Clustering induces redistribution of syndecan-4 core protein into raft membrane domains. J Biol Chem (2002) 1.43
Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1. J Biol Chem (2008) 1.38
Syndecan-4 regulates subcellular localization of mTOR Complex2 and Akt activation in a PKCalpha-dependent manner in endothelial cells. Mol Cell (2008) 1.36
Suppression of RhoG activity is mediated by a syndecan 4-synectin-RhoGDI1 complex and is reversed by PKCalpha in a Rac1 activation pathway. J Cell Biol (2009) 1.36
Loss of skeletal muscle HIF-1alpha results in altered exercise endurance. PLoS Biol (2004) 1.36
Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. Proc Natl Acad Sci U S A (2003) 1.33
Syndecan-4 clustering induces cell migration in a PDZ-dependent manner. Circ Res (2006) 1.31
Fibroblast growth factor 2 endocytosis in endothelial cells proceed via syndecan-4-dependent activation of Rac1 and a Cdc42-dependent macropinocytic pathway. J Cell Sci (2004) 1.30
Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells. Cell Signal (2004) 1.29
Fibroblast growth factor-specific modulation of cellular response by syndecan-4. J Cell Biol (2002) 1.26
Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis. J Appl Physiol (1985) (2003) 1.25
The extracellular matrix and blood vessel formation: not just a scaffold. J Cell Mol Med (2007) 1.25
Endothelial ERK signaling controls lymphatic fate specification. J Clin Invest (2013) 1.24
Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein. Mol Cell Biol (2008) 1.23
PKCalpha activates eNOS and increases arterial blood flow in vivo. Circ Res (2005) 1.22
Non-canonical fibroblast growth factor signalling in angiogenesis. Cardiovasc Res (2007) 1.22
Endothelial deletion of murine Jag1 leads to valve calcification and congenital heart defects associated with Alagille syndrome. Development (2012) 1.21
Endothelial expression of beta1 integrin is required for embryonic vascular patterning and postnatal vascular remodeling. Mol Cell Biol (2007) 1.19
Delayed arteriogenesis in hypercholesterolemic mice. Circulation (2005) 1.19
Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res (2008) 1.17
Transcriptional profiling in coronary artery disease: indications for novel markers of coronary collateralization. Circulation (2006) 1.17
Expression of VEGF and angiopoietins-1 and -2 during ischemia-induced coronary angiogenesis. Am J Physiol Heart Circ Physiol (2003) 1.16
Arteriogenesis: noninvasive quantification with multi-detector row CT angiography and three-dimensional volume rendering in rodents. Radiology (2006) 1.16
Phosphorylation of VE-cadherin controls endothelial phenotypes via p120-catenin coupling and Rac1 activation. Am J Physiol Heart Circ Physiol (2010) 1.15
Restoration of deficient membrane proteins in the cardiomyopathic hamster by in vivo cardiac gene transfer. Circulation (2002) 1.14
Humoral and cellular factors responsible for coronary collateral formation. Am J Cardiol (2006) 1.14
Copper chelation represses the vascular response to injury. Proc Natl Acad Sci U S A (2003) 1.13
High-resolution quantitative computed tomography demonstrating selective enhancement of medium-size collaterals by placental growth factor-1 in the mouse ischemic hindlimb. Circulation (2006) 1.13
Inhibition of microRNA-29 enhances elastin levels in cells haploinsufficient for elastin and in bioengineered vessels--brief report. Arterioscler Thromb Vasc Biol (2011) 1.11
Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol (2009) 1.10
Micro computed tomography for vascular exploration. J Angiogenes Res (2010) 1.09
Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed? J Am Coll Cardiol (2005) 1.09
VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Mol Med (2014) 1.08
Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacol (2005) 1.08
Chromogranin B regulates calcium signaling, nuclear factor kappaB activity, and brain natriuretic peptide production in cardiomyocytes. Circ Res (2008) 1.08
Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry (2003) 1.07
Dll4-Notch signaling determines the formation of native arterial collateral networks and arterial function in mouse ischemia models. Development (2013) 1.07
The antiangiogenic activity of rPAI-1(23) inhibits vasa vasorum and growth of atherosclerotic plaque. Circ Res (2009) 1.07
Endothelial-to-mesenchymal transition drives atherosclerosis progression. J Clin Invest (2015) 1.06
Endothelial nuclear factor-κB-dependent regulation of arteriogenesis and branching. Circulation (2012) 1.06
Decorin inhibition of PDGF-stimulated vascular smooth muscle cell function: potential mechanism for inhibition of intimal hyperplasia after balloon angioplasty. Am J Pathol (2003) 1.06
Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc Med (2003) 1.06
Protein kinase C (PKC) delta regulates PKCalpha activity in a Syndecan-4-dependent manner. J Biol Chem (2002) 1.06
The spatial distribution of inositol 1,4,5-trisphosphate receptor isoforms shapes Ca2+ waves. J Biol Chem (2007) 1.05
Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation. Proc Natl Acad Sci U S A (2008) 1.05
Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci U S A (2002) 1.03
Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell (2013) 1.01
An engineered VEGF-activating zinc finger protein transcription factor improves blood flow and limb salvage in advanced-age mice. FASEB J (2006) 1.01
Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. Cardiovasc Res (2005) 1.01
Cleavage of syndecan-4 by ADAMTS1 provokes defects in adhesion. Int J Biochem Cell Biol (2008) 1.01
Syndecan-4 signaling at a glance. J Cell Sci (2013) 1.01
Endothelial cell-dependent regulation of arteriogenesis. Circ Res (2013) 1.00
Synectin/syndecan-4 regulate coronary arteriolar growth during development. Dev Dyn (2007) 1.00
Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL. J Lipid Res (2008) 0.99
NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth. J Clin Invest (2013) 0.99
Angiogenesis in the human heart: gene and cell therapy. Angiogenesis (2005) 0.97
Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. Clin Cancer Res (2009) 0.96
Effects of cell grafting on coronary remodeling after myocardial infarction. J Am Heart Assoc (2013) 0.95
Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg (2002) 0.95
Transmembrane protein ESDN promotes endothelial VEGF signaling and regulates angiogenesis. J Clin Invest (2013) 0.95
Angiopoietin-2 secretion by endothelial cell exosomes: regulation by the phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial nitric oxide synthase (eNOS) and syndecan-4/syntenin pathways. J Biol Chem (2013) 0.95
State-of-the-Art Methods for Evaluation of Angiogenesis and Tissue Vascularization: A Scientific Statement From the American Heart Association. Circ Res (2015) 0.94
Syndecan 4 regulates FGFR1 signaling in endothelial cells by directing macropinocytosis. Sci Signal (2012) 0.94
Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum (2007) 0.94
Increased responsiveness of hypoxic endothelial cells to FGF2 is mediated by HIF-1alpha-dependent regulation of enzymes involved in synthesis of heparan sulfate FGF2-binding sites. J Cell Sci (2002) 0.94
Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation. Am J Physiol Regul Integr Comp Physiol (2005) 0.93